Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

144 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Single cell multiomics reveal divergent effects of DNMT3A and TET2 mutant clonal hematopoiesis in inflammatory response.
Mohammed Ismail W, Fernandez J, Binder M, Lasho TL, Kim M, Geyer S, Mazzone A, Finke CM, Mangaonkar AA, Lee JH, Wang L, Kim KH, Simon VA, Rakhshan Rohakthar F, Munankarmy A, Byeon SK, Schwager SM, Harington JJ, Snyder MR, Robertson KD, Pandey A, Wieben ED, Chia N, Gaspar-Maia A, Patnaik MM. Mohammed Ismail W, et al. Among authors: finke cm. Blood Adv. 2024 Dec 4:bloodadvances.2024014467. doi: 10.1182/bloodadvances.2024014467. Online ahead of print. Blood Adv. 2024. PMID: 39631069
Targeted deep sequencing in primary myelofibrosis.
Tefferi A, Lasho TL, Finke CM, Elala Y, Hanson CA, Ketterling RP, Gangat N, Pardanani A. Tefferi A, et al. Among authors: finke cm. Blood Adv. 2016 Nov 30;1(2):105-111. doi: 10.1182/bloodadvances.2016000208. eCollection 2016 Dec 13. Blood Adv. 2016. PMID: 29296803 Free PMC article.
Targeted next-generation sequencing in blast phase myeloproliferative neoplasms.
Lasho TL, Mudireddy M, Finke CM, Hanson CA, Ketterling RP, Szuber N, Begna KH, Patnaik MM, Gangat N, Pardanani A, Tefferi A. Lasho TL, et al. Among authors: finke cm. Blood Adv. 2018 Feb 27;2(4):370-380. doi: 10.1182/bloodadvances.2018015875. Blood Adv. 2018. PMID: 29467191 Free PMC article.
SF3B1-mutant CMML defines a predominantly dysplastic CMML subtype with a superior acute leukemia-free survival.
Wudhikarn K, Loghavi S, Mangaonkar AA, Al-Kali A, Binder M, Carr R, Reichard K, Finke C, Howard M, Gangat N, Tefferi A, Komrokji R, Ali N, Lasho T, Ketterling R, Padron E, Patnaik MM. Wudhikarn K, et al. Blood Adv. 2020 Nov 24;4(22):5716-5721. doi: 10.1182/bloodadvances.2020003345. Blood Adv. 2020. PMID: 33216886 Free PMC article. No abstract available.
CSF3R T618I mutant chronic myelomonocytic leukemia (CMML) defines a proliferative CMML subtype enriched in ASXL1 mutations with adverse outcomes.
Bezerra ED, Lasho TL, Finke CM, Saliba AN, Elliott MA, Pardanani AD, Gangat N, Mangaonkar AA, Ketterling RP, Tefferi A, Solary E, Patnaik MM. Bezerra ED, et al. Among authors: finke cm. Blood Cancer J. 2021 Mar 11;11(3):54. doi: 10.1038/s41408-021-00449-9. Blood Cancer J. 2021. PMID: 33707412 Free PMC article. No abstract available.
144 results